Quadrant Biosciences Inc ngumumake dina iki yen Kantor Paten lan Merek Dagang Amerika Serikat (USPTO) wis ngetokake perusahaan lan mitra, Yayasan Riset SUNY lan Yayasan Riset Negara Penn, Paten AS No. 11,242,563 (Analisis Gangguan Spektrum Autisme). Paten kasebut nyakup dhasar ilmiah kanggo pangembangan bantuan diagnostik autisme multiomik adhedhasar saliva, sing bisa mbedakake individu sing duwe autis saka individu sing duwe perkembangan khas utawa keterlambatan perkembangan kanthi ngukur tingkat microRNA (miRNA) lan mikrobioma ing saliva. Quadrant Biosciences, perusahaan Life Science adhedhasar ing Syracuse, New York, nggunakake urutan generasi sabanjure lan AI kanggo ngembangake diagnostik molekuler adhedhasar RNA kanggo macem-macem kondisi medis.
"Nerbitake paten resmi AS kanggo karya kita babagan pangembangan bantuan diagnostik berbasis saliva kanggo autisme minangka pengakuan sing jelas babagan kebaruan lan sarana pendekatan sing dikembangake," ujare Frank Middleton, PhD, Profesor ing SUNY Upstate Medical. Universitas lan salah sawijining peneliti utama ing mburi riset paten. "Fokus kita kanggo nggunakake pendekatan multiomik sing nggabungake fitur RNA regulasi saka host manungsa uga microbiome lisan wis menehi wawasan sing akeh babagan kelainan spektrum autisme."
Dr Steve Hicks, MD, PhD saka Penn State College of Medicine, penemu kunci liyane ing paten, nerangake pinunjul klinis potensial. "Muga-muga alat molekuler iki bakal nambah kemampuan dokter kanggo mbedakake bocah-bocah ing spektrum autisme saka kanca-kanca kanthi penundaan perkembangan non-autis, ngidini diagnosis awal lan wiwitan terapi perilaku. Kajaba iku, "dheweke terus, "tonggak sejarah iki mbuktekake inovasi sing ana ing riset Quadrant Biosciences lan ningkatake tujuan kolektif kita kanggo ningkatake perawatan medis kanggo bocah-bocah sing kelainan spektrum autisme."
"We are remen sing USPTO wis diwenehi paten kita kanggo karya groundbreaking iki," ngandika Rich Uhlig, Pendhiri lan CEO saka Quadrant Biosciences. "Iki ndhukung taun-taun upaya R&D sing ketat kanggo madhangi faktor epigenetik sing ana gandhengane karo autisme, lan ngembangake biomarker diagnostik novel kanggo ngatasi kebutuhan sing penting kanggo nyepetake pengembaraan diagnostik autisme sing berpanjangan kanggo wong tuwa lan pengasuh."
APA sing kudu dijupuk saka ARTIKEL INI:
- “The issuing of an official US patent for our work on development of a saliva-based diagnostic aid for autism is a clear acknowledgement of the novelty and utility of the approach that we developed,”.
- The patent covers the scientific foundation for the development of a saliva-based, multiomic autism diagnostic aid, that can differentiate individuals with autism from individuals with typical development or developmental delays by measuring microRNA (miRNA) and microbiome levels in saliva.
- “This supports our years of rigorous R&D efforts to illuminate the epigenetic factors associated with autism, and develop novel diagnostic biomarkers to address the urgent need to shorten the protracted autism diagnostic odyssey for parents and caregivers.
